Pharvaris N.V. Company Profile
NASDAQ: PHVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 31.68 0.00%
Pharvaris N.V. at a glance
Pharvaris N.V. (NASDAQ: PHVS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Zug, Netherlands. Pharvaris N.V. is led by Mr. Berndt Axel Edvard Modig CPA, M.B.A. and employs about 148 people. The company's shares have traded publicly since 2021.
At a market capitalization of $2.17 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001830487, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Pharvaris N.V. do?
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Business description based on the company's public filings.
Company information
- Legal name
- Pharvaris N.V.
- Ticker
- NASDAQ: PHVS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Berndt Axel Edvard Modig CPA, M.B.A.
- Employees
- 148
- Headquarters
- Grafenauweg 8, Zug, Netherlands
- Phone
- 31 712036410
- Website
- pharvaris.com
- IPO year
- 2021
- Market cap
- $2.17B
- SEC CIK
- 0001830487
Companies similar to Pharvaris N.V.
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VERAVera Therapeutics Inc. Class A | 30.25 | +2.82% | $2.18B | vs PHVS |
| AUPHAurinia Pharmaceuticals Inc | 16.01 | +2.04% | $2.13B | vs PHVS |
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs PHVS |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs PHVS |
| VRDNViridian Therapeutics Inc. | 18.28 | +0.33% | $2.07B | vs PHVS |
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs PHVS |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs PHVS |
| SDGRSchrodinger Inc. | 27.29 | -5.57% | $2.04B | vs PHVS |